Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes
Elizabeth L Eby,1 Kate Van Brunt,2 Cynthia Brusko,3 Bradley Curtis,4 Maureen J Lage5 1Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis IN USA; 2Eli Lilly and Co., Windlesham, UK; 3Lilly USA, LLC, Indianapolis, IN, USA; 4Eli Lilly a...
Enregistré dans:
Auteurs principaux: | Eby EL, Van Brunt K, Brusko C, Curtis B, Lage MJ |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2015
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3b00f7e19d5c4ce8b901e842577cae8b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach
par: Pollock RF, et autres
Publié: (2018) -
The value of patient-reported outcomes in patients with type 2 diabetes mellitus receiving insulin therapy: assessment of quality of life and hypoglycemia problems
par: Tat'yana Ivanovna Ionova, et autres
Publié: (2015) -
Association Between Knowledge of Hypoglycemia and Likelihood of Experiencing Hypoglycemia Among Patients with Insulin-Treated Diabetes Mellitus
par: Almigbal TH
Publié: (2021) -
RELUCTANCE OF PATIENTS WITH DIABETES MELLITUS TO INSULIN THERAPY; PSYCHOLOGICAL INSULIN RESISTANCE
par: Umair Ali, et autres
Publié: (2021) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
par: Ivan Ivanovich Dedov, et autres
Publié: (2014)